NextCure director receives 2,340 stock options

NextCure, Inc. director Ellen Feigal received a grant of stock options covering 2,340 shares of common stock.

Rhea-AI Filing Summary

NextCure, Inc. director Ellen Feigal received a grant of stock options covering 2,340 shares of common stock. These options have an exercise price of $2.02 per share and expire on June 17, 2036.

The option vests in full on the earlier of June 18, 2027 or the date of NextCure’s 2027 Annual Meeting of Stockholders. Following this grant, Feigal holds 2,340 stock options directly related to this award.

Insider Trade Summary

Grant/Award: 2,340 shares

Grant/Award 1 txn

Insider Feigal Ellen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,340	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 2,340 contracts (Direct)

Footnotes (1)

1. F1. The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

Key Figures

Options granted: 2,340 options Exercise price: $2.02 per share Expiration date: June 17, 2036 +3 more

6 metrics

Options granted 2,340 options Stock Option (Right to Buy) grant to director

Exercise price $2.02 per share Conversion or exercise price of stock options

Expiration date June 17, 2036 Option term end date

Underlying shares 2,340 shares Common Stock underlying the options

Post-grant derivative holdings 2,340 options Total options following this transaction

Vesting date trigger June 18, 2027 Earlier of this date or 2027 Annual Meeting

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, vests in full, Annual Meeting of Stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy) granted to the director"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition of options"

vests in full financial

"The option vests in full on the earlier of June 18, 2027"

Annual Meeting of Stockholders financial

"earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NextCure (NXTC) director Ellen Feigal report on this Form 4?

Ellen Feigal reported receiving a grant of stock options for 2,340 shares of NextCure common stock. The options are a compensation-related award, not an open-market trade, and give her the right to buy shares at a fixed exercise price of $2.02.

What are the key terms of Ellen Feigal’s NextCure (NXTC) stock options?

The grant covers 2,340 shares with a $2.02 exercise price and an expiration date of June 17, 2036. These options represent a right to buy NextCure common stock in the future if the vesting conditions are satisfied.

When do Ellen Feigal’s NextCure (NXTC) stock options vest?

The options vest in full on the earlier of June 18, 2027 or the date of NextCure’s 2027 Annual Meeting of Stockholders. Vesting must occur before the options can be exercised to purchase common shares.

Is Ellen Feigal buying or selling NextCure (NXTC) shares in this filing?

This filing shows an acquisition of stock options as a grant, not a market purchase or sale of shares. The transaction is classified as a grant or award acquisition, giving a future right to buy 2,340 shares at $2.02.

How many NextCure (NXTC) derivative securities does Ellen Feigal hold after this grant?

After this transaction, Ellen Feigal holds 2,340 stock options related to this award. These options are derivative securities tied to NextCure common stock and reflect her position from this specific grant reported in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feigal Ellen

(Last) (First) (Middle)

C/O NEXTCURE, INC.

9000 VIRGINIA MANOR ROAD, SUITE 200

(Street)

BELTSVILLE MARYLAND 20705

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.02	06/18/2026		A		2,340		(1)	06/17/2036	Common Stock	2,340	$0	2,340	D

Explanation of Responses:

1. The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

	/s/ Steven P. Cobourn, as attorney-in-fact for Ellen Feigal	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)